A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Investigate the Efficacy and Safety of Ofatumumab Injection for Subcutaneous Use in Subjects With Pemphigus Vulgaris
Phase of Trial: Phase III
Latest Information Update: 23 Jun 2017
At a glance
- Drugs Ofatumumab (Primary)
- Indications Pemphigus vulgaris
- Focus Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis; Stiefel Laboratories
- 01 Jun 2017 This study has been completed in Croatia - MIZ as per European Clinical Trials Database
- 07 Apr 2017 Planned End Date changed from 1 Mar 2017 to 30 Sep 2017.
- 07 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 30 Sep 2017.